- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03763747
Scoreflex NC - Scoring PTCA Catheter
Scoreflex NC - Scoring PTCA Catheter: A Prospective, Open Label, Multi-center, Single Arm, Observational Study Designed to Evaluate the Safety and Device Procedural Success of the Scoreflex NC Scoring PTCA Catheter in Subjects With Stenotic Coronary Arteries During Percutaneous Coronary Intervention.
A prospective, open label, multi-center, single arm, observational study designed to evaluate the acute safety and device procedural success of the Scoreflex NC Scoring Percutaneous Transluminal Coronary Angioplasty (PTCA) catheters in subjects with stenotic coronary arteries during percutaneous coronary intervention.
Two-hundred (200) subjects will be treated at up to 15 U.S. sites with the Scoreflex NC Scoring PTCA catheter during their index procedure. All subjects will be screened according to the protocol inclusion and exclusion criteria and will be followed through hospital discharge.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Florida
-
Gainesville, Florida, United States, 32605
- The Cardiac and Vascular Institute Research Foundation
-
Miami, Florida, United States, 33136
- University of Miami
-
-
Georgia
-
Atlanta, Georgia, United States, 30309
- Piedmont Heart Institute
-
Decatur, Georgia, United States, 30033
- Atlanta VA Healthcare System
-
-
Maryland
-
Salisbury, Maryland, United States, 21804
- Delmarva Heart Research Foundation Inc./Peninsula Regional Medical Center
-
-
Minnesota
-
Saint Cloud, Minnesota, United States, 56303
- CentraCare Heart and Vascular Center
-
-
Mississippi
-
Tupelo, Mississippi, United States, 38801
- Cardiology Associates Research, LLC
-
-
New Jersey
-
Browns Mills, New Jersey, United States, 08015
- Deborah Heart and Lung Center
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- The Lindner Research Center/The Christ Hospital Heart and Vascular
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Clinical Inclusion Criteria
- Subject is ≥ 18 years of age.
- Subject or a legally authorized representative must provide written informed consent prior to any study related procedures.
- Subject must agree not to participate in any other clinical study during hospitalization for the index procedure that would interfere with the endpoints of this study.
Subjects must have a single or double vessel coronary artery disease (CAD) and clinical evidence of ischemic heart disease, such as CAD, stable / unstable angina or silent ischemia.
Angiographic Inclusion Criteria
- Subject must have de novo or restenotic lesion(s) in native coronary arteries, including in-stent restenosis suitable for percutaneous coronary intervention.
- A maximum of two lesions, including at least one target lesion, in up to two coronary arteries.
- Target lesion must have a reference vessel diameter (RVD) between 1.75 and 4.0 mm by visual estimation.
- Target lesion(s) must have a diameter stenosis of ≥70% by visual estimation and may include chronic total occlusions (CTO).
- The non-target lesion must be located in different coronary artery from the Target lesion.
- Treatment of non-target lesion, if any, must be completed prior to treatment of target lesion and must be deemed a clinical angiographic success as visually assessed by the physician.
Clinical Exclusion Criteria:
- Subject with a known hypersensitivity or contraindication to aspirin, heparin, bivalirudin, anti-platelet medications, or sensitivity to contrast media which cannot be adequately pre-medicated.
- Subject with known diagnosis of STEMI or NSTEMI at index presentation or within 7 days of study screening.
- Subject with known pregnancy or is nursing. Women of child-bearing potential should have a documented negative pregnancy test within 7 days before index procedure.
- Planned or actual target lesion treatment with an unapproved device, atherectomy, laser, cutting balloon or thrombectomy during the index procedure.
- A serum creatinine level > 2.0 mg/dl within 7 days prior to index procedure.
- Cerebrovascular accident (CVA) within the past 6 months.
- Active peptic ulcer or active gastrointestinal (GI) bleeding within the past 6 months.
- Subject has a known left ventricular ejection fraction (LVEF) <30% (LVEF may be obtained at the time of the index procedure if the value is unknown, if necessary)
Target lesion located within an arterial or saphenous vein graft or graft anastomosis
Angiographic Exclusion Criteria
- More than two lesions requiring treatment.
- Target lesion longer than 30 mm by visual estimation.
- Extreme angulation (90º or greater) proximal to or within the target lesion.
- Previous percutaneous intervention of lesions in a target vessel (including side branches) conducted within 9 months before the study procedure and located within 10 mm from the current target lesion.
- Target lesion demonstrating severe dissection prior to planned deployment of the Scoreflex NC device
- Unprotected left main coronary artery disease. (Greater than 50% diameter stenosis)
- Coronary artery spasm of the target vessel in the absence of a significant stenosis.
- Target lesion with angiographic presence of probable or definite thrombus.
- Target lesion involves a bifurcation requiring treatment with more than one stent or pre-dilatation of a side branch >2.0 mm in diameter.
Non-target lesion to be treated during the index procedure meets any of the following criteria:
- Located within a bypass graft (venous or arterial)
- Left main location
- Chronic total occlusion
- Involves a bifurcation (e.g., bifurcations requiring treatment with more than 1 stent)
- Treatment not deemed a clinical angiographic success
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Scoreflex NC Scoring PTCA Catheter
Single arm with investigational Scoreflex NC Scoring PTCA catheters
|
To dilate coronary arteries during the subject's index procedure with Scoreflex NC Scoring PTCA catheters
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Device Procedural Success
Time Frame: Peri-procedural (at Day 0)
|
Device procedural success consisting of the following:
|
Peri-procedural (at Day 0)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Angiographic Procedural Success
Time Frame: Peri-procedural (at Day 0)
|
Angiographic Procedural Success defined as Final diameter stenosis ≤ 50% in at least one of the Scoreflex NC attempted lesions following completion of the interventional procedure, including adjunctive stenting
|
Peri-procedural (at Day 0)
|
Number of Participants With In-hospital Major Adverse Cardiac Events (MACE)
Time Frame: Endpoints will be measured through hospital discharge (expected to be within 24 hours)
|
In-hospital Major Adverse Cardiac Events (MACE), a composite of:
|
Endpoints will be measured through hospital discharge (expected to be within 24 hours)
|
Number of Participants With In-hospital Stent Thrombosis (ST) Within the Target Vessel
Time Frame: Endpoint will be measured through hospital discharge (expected to be within 24 hours)
|
In-hospital stent thrombosis (ST) within the Target Vessel
|
Endpoint will be measured through hospital discharge (expected to be within 24 hours)
|
Number of Participants With Clinically Significant Arrhythmias (Requiring Intervention)
Time Frame: Endpoint will be measured through hospital discharge (expected to be within 24 hours)
|
Clinically Significant Arrhythmias (Requiring Intervention)
|
Endpoint will be measured through hospital discharge (expected to be within 24 hours)
|
Number of Scoreflex NC Scoring Catheters That Had Occurrence of Balloon Rupture
Time Frame: Peri-procedural
|
Occurrence of Scoreflex NC Study Balloon rupture
|
Peri-procedural
|
Number of Participants That Had Improvement in Minimum Lumen Diameter (MLD) Following Use of Scoreflex NC Catheter (Measured by Quantitative Coronary Angiography (QCA))
Time Frame: Peri-procedural
|
Improvement in Minimum Lumen Diameter (MLD) following use of Scoreflex NC catheter (measured by QCA). Improvement in MLD is defined as MLD post use of Scoreflex as greater than MLD from baseline. |
Peri-procedural
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
General Publications
- Kandzari D, Hearne S, Kumar G, Sachdeva R, Adams G, Blossom B, Dahle T, Sanghvi K, Cohen MG, Imperi G, Riley R, Almonacid AP. Procedural Effectiveness With a Focused Force Scoring Angioplasty Catheter: Procedural and Clinical Outcomes From the Scoreflex NC Trial. Cardiovasc Revasc Med. 2022 Feb;35:85-90. doi: 10.1016/j.carrev.2021.03.013. Epub 2021 Mar 20.
- Louvard Y, Medina A. Definitions and classifications of bifurcation lesions and treatment. EuroIntervention. 2015;11 Suppl V:V23-6. doi: 10.4244/EIJV11SVA5.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- VP-0730
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myocardial Ischemia
-
Recardio, Inc.CompletedAcute Myocardial Infarction | STEMI - ST Elevation Myocardial Infarction | Acute Myocardial IschemiaNetherlands, Hungary, Austria, Poland, Belgium
-
University of Roma La SapienzaCompletedRosuvastatin in Preventing Myonecrosis in Elective Percutaneous Coronary Interventions (PCIs) (ROMA)Periprocedural Myocardial NecrosisItaly
-
University Hospital "Sestre Milosrdnice"CompletedSTEMI - ST Elevation Myocardial Infarction | Myocardial ReperfusionCroatia
-
Fundacio Privada Mon Clinic BarcelonaMiracor Medical SANot yet recruiting
-
Lokien van NunenMaquet Cardiovascular; Stichting Toegepaste Wetenschappen (project number 11052)CompletedAcute Myocardial Infarction | Persisting Ischemia | No ReflowNetherlands
-
Deutsches Herzzentrum MuenchenCompletedInfarction, MyocardialGermany
-
Tomsk National Research Medical Center of the Russian...CompletedMyocardial Infarction | Myocardial Injury | STEMI | Myocardial NecrosisRussian Federation
-
Barts & The London NHS TrustUniversity College, London; Queen Mary University of LondonCompletedAcute Myocardial InfarctionSwitzerland, Denmark, United Kingdom
-
University Hospital, ToulouseThoratec CorporationWithdrawnChronic Myocardial IschemiaFrance
-
Foundation IRCCS San Matteo HospitalFondazione Poliambulanza Istituto Ospedaliero; Azienda Ospedaliera Ordine Mauriziano... and other collaboratorsWithdrawnST-elevation Myocardial InfarctionItaly
Clinical Trials on Scoreflex NC Scoring PTCA catheter
-
BrosMed Medical Co., LtdCompleted
-
JW Medical Systems LtdNot yet recruiting
-
Deutsches Herzzentrum MuenchenSIS Medical AGCompletedCalcified Coronary Artery Disease (Grade 3)Germany, Switzerland
-
OrbusNeichCCRC Medtech (Shanghai) Co., Ltd.Recruiting
-
AngioScore, Inc.CompletedMyocardial Ischemia | Coronary Artery DiseaseUnited States
-
AlvimedicaCompletedVascular Diseases | Coronary Artery Disease | Coronary DiseaseTurkey
-
Boston Scientific CorporationCompletedCoronary Artery DiseaseUnited States
-
VentureMed Group Inc.Terminated
-
Flanders Medical Research ProgramAngioScore, Inc.CompletedPeripheral Arterial Occlusive DiseaseBelgium, Germany
-
TriReme Medical, LLCCompleted